Analyst firms · H.C. Wainwright · RARE

H.C. Wainwright RARE price target and rating history

Ultragenyx Pharmaceutical Inc. (RARE) · Health Care

H.C. Wainwright rates Ultragenyx Pharmaceutical Inc. (RARE) Buy with a $80 price target, as of its latest action on Jul 28, 2025. It has published 3 rating actions on RARE since September 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a RARE price target in the last 12 months, the median target is $16.

Current rating
Buy
Price target
$80
Median target, all firms
$16
Actions on RARE
3

H.C. Wainwright price target on RARE

$106$93$8020222023202420252026
H.C. Wainwright price target on RARE, each point a stated target, September 2021 to July 2025.

Every H.C. Wainwright rating on RARE

How other firms rate RARE

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSNeutral$16Oct 15, 2026
BofA SecuritiesNeutralSep 3, 2026
William BlairMkt PerformSep 3, 2026
Evercore ISIIn-line$16Sep 3, 2026
Robert W. BairdNeutral$16Sep 3, 2026
Wells FargoEqual Weight$18Sep 3, 2026
Goldman SachsNeutral$25Mar 24, 2026

Questions about H.C. Wainwright and RARE

What is H.C. Wainwright's price target for RARE?
H.C. Wainwright's latest stated price target for Ultragenyx Pharmaceutical Inc. (RARE) is $80, from its action on Jul 28, 2025.
What is H.C. Wainwright's rating on RARE?
H.C. Wainwright rates RARE Buy, a bullish rating, as of Jul 28, 2025.
When did H.C. Wainwright last change its view on RARE?
On Jul 28, 2025, H.C. Wainwright resumes coverage at Buy, price target $80.
How does H.C. Wainwright's RARE target compare with other analysts?
Across 5 firms with a RARE price target in the last 12 months, the median target is $16.

More RARE rating histories

All H.C. Wainwright ratingsRARE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.